This story is just the latest example in the ongoing issues GLP-1s face when it comes to coverage. As a result, coverage providers have struggled to include the medications, especially considering the wide swath of indications they can be prescribed for. Pharmaceutical Executive: What impact has research into the cardiometabolic benefit of GLP-1s had on coverage? Susan Thomas: Investment in GLP-1s is certainly a cost consideration. But when you commit to the long-term benefit, that's when you'll see those cost savings materialize.